Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYN008 vs Omalizumab in Refractory Chronic Spontaneous Urticaria
NCT04944602Phase 3Unknown
- Sponsor
- CSPC Baike Biopharmaceutical
- Start
- Jul 2021
- Primary completion
- Mar 2023
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 3 trial of omalizumab biosimilar SYN008 in chronic spontaneous urticaria (CSU), sponsored by CSPC Baike Biopharmaceutical. Status: unknown.
02
Drugs
omalizumab biosimilar SYN008
03
Conditions
chronic spontaneous urticaria (CSU)
Beyond the preview
Go deeper on NCT04944602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04944602.